Arcutis Biotherapeutics (Nasdaq:ARQT) - Cotización, noticias y análisis

Resumen de acción ARQT

Arcutis Biotherapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de tratamientos para enfermedades dermatológicas.

Acerca de la empresa

ARQT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 91.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 39.32%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Arcutis Biotherapeutics, Inc.

POINT Biopharma Global

NasdaqCM:PNT

US$1.3b

TG Therapeutics

NasdaqCM:TGTX

US$2.2b

Verve Therapeutics

NasdaqGS:VERV

US$575.3m

Arcellx

NasdaqGS:ACLX

US$2.8b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Arcutis Biotherapeutics
Historical stock prices
Current Share Price	US$8.59
52 Week High	US$15.21
52 Week Low	US$1.76
Beta	1.14
1 Month Change	-7.34%
3 Month Change	62.08%
1 Year Change	-37.57%
3 Year Change	-71.88%
5 Year Change	n/a
Change since IPO	-60.60%

Noticias y actualizaciones recientes

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

Sep 26

Rentabilidad de los accionistas

	ARQT	US Biotechs	Mercado US
7D	-9.1%	1.0%	1.2%
1Y	-37.6%	0.7%	24.9%

Rentabilidad vs. Industria: ARQT obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 1.1%.

Rentabilidad vs. Mercado: ARQT obtuvo unos resultados inferiores a los del mercado US, que fue del 24.7% el año pasado.

Volatilidad de los precios

Is ARQT's price volatile compared to industry and market?
ARQT volatility
ARQT Average Weekly Movement	14.6%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de ARQT ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ARQT(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	296	Frank Watanabe	www.arcutis.com

Arcutis Biotherapeutics, Inc. es una empresa biofarmacéutica dedicada al desarrollo y comercialización de tratamientos para enfermedades dermatológicas. Su principal producto candidato es ARQ-151, una crema tópica de roflumilast que ha completado los ensayos clínicos de fase III para el tratamiento de la psoriasis en placas y la dermatitis atópica. La empresa también está desarrollando ARQ-154, un ZORYVE tópico para el tratamiento de la psoriasis corporal y del cuero cabelludo y la dermatitis seborreica; ARQ-252, un inhibidor tópico selectivo de la janus quinasa tipo 1 para el eccema de manos y el vitíligo; ARQ-255, un inhibidor tópico de la JAK1 para la alopecia areata; y ARQ-234, una proteína de fusión CD200R para el tratamiento de la dermatitis atópica de moderada a grave.

Resumen de fundamentos de Arcutis Biotherapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Arcutis Biotherapeutics con su capitalización de mercado?
Estadísticas fundamentales de ARQT
Capitalización bursátil	US$1.01b
Beneficios(TTM)	-US$262.14m
Ingresos (TTM)	US$59.61m

16.6x

Ratio precio-ventas (PS)

-3.8x

Ratio precio-beneficio (PE)

¿Está ARQT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ARQT
Ingresos	US$59.61m
Coste de los ingresos	US$4.99m
Beneficio bruto	US$54.62m
Otros gastos	US$316.76m
Beneficios	-US$262.14m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.28
Margen bruto	91.63%
Margen de beneficio neto	-439.79%
Ratio deuda/patrimonio	227.6%

¿Cómo se ha desempeñado ARQT a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ARQT

Recompensas

Análisis de riesgos

Competidores de Arcutis Biotherapeutics, Inc.

NasdaqCM:PNT

US$1.3b

NasdaqCM:TGTX

US$2.2b

NasdaqGS:VERV

US$575.3m

NasdaqGS:ACLX

US$2.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023

Consensus revenue estimates increase by 26%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

New minor risk - Financial position

Price target decreased by 8.5% to US$41.71

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Announces Zoryve® (Roflumilast) Cream 0.3% Included in Preferred Position on National Formularies for CVS Caremark

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Price target decreased by 9.2% to US$45.50

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Director exercised options and sold US$104k worth of stock

Director exercised options and sold US$88k worth of stock

Director exercised options and sold US$130k worth of stock

Arcutis Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Director exercised options and sold US$102k worth of stock

Forecast to breakeven in 2025

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for ZORYVE Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

Arcutis Biotherapeutics, Inc. Enrolls First Patient in Phase 1B Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. Announces the Publication of Positive Patient-Reported Outcome Itch Data from Its Phase 2B Study Evaluating Once-Daily Roflumilast Cream (0.3% and 0.15%) in Adults with Chronic Plaque Psoriasis

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream

Consensus forecasts updated

Arcutis Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Consensus revenue estimates fall by 12%

Consensus forecasts updated